ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2513

Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

Laura Coates1, Andrew Bushmakin 2, Oliver FitzGerald 3, Dafna Gladman 4, Lara Fallon 5, Joseph Cappelleri 2, Ming-Ann Hsu 6 and Philip Helliwell 7, 1University of Oxford, Oxford, United Kingdom, 2Pfizer Inc, Groton, CT, 3University College Dublin, Dublin, Ireland, 4University of Toronto, Toronto, ON, Canada, 5Pfizer Inc, Montreal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7University of Leeds, Leeds, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Disease Activity and clinical trials, patient-reported outcome measures, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a complex heterogeneous disease associated with multiple domains. Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure for PsA, developed to assess improvements in multiple clinical outcomes in response to treatment using a single instrument.1 The objective of this post hoc analysis was to evaluate associations between PASDAS and a set of patient-reported outcomes (PROs).

Methods: All available data from two Phase 3 studies in patients with PsA (OPAL Broaden [12 months; NCT01877668]; OPAL Beyond [6 months; NCT01882439])2,3 were analyzed. PASDAS (score range 0–10) is based on the following measures: Patient’s Global Assessment of PsA Visual Analog Scale (VAS); Physician’s Global Assessment of PsA VAS; tender and swollen joint counts; Leeds Enthesitis count; tender dactylitis count; Short-Form 36 Health Survey Physical Component Summary (SF-36 PCS); and C-reactive protein. PASDAS cut-offs for low and high disease activity are 3.2 and 5.4, respectively.4 A set of PROs was analyzed (Table 1). A repeated measures regression model was used to evaluate the relationship between PASDAS and PROs. A sensitivity analysis to assess the linearity assumption was performed.

Results: An approximately linear relationship was observed between PASDAS and PROs, which was consistent across all PROs and both studies. For example, in OPAL Broaden, a 1‑point difference in PASDAS was associated with a mean (95% CI) difference in Patient’s Assessment of Arthritis Pain VAS (Pain) score of 9.9 mm (9.4, 10.4) (OPAL Beyond: 10.7 mm [10.1, 11.2]). Mean Pain scores (95% CI) corresponding to PASDAS low and high disease activity cut-offs, respectively, were 26.3 mm (25.0, 27.5) and 48.0 mm (46.7, 49.4) in OPAL Broaden (OPAL Beyond: 25.4 mm [23.7, 27.1] and 48.8 mm [47.4, 50.3], respectively) (Figure 1). In OPAL Broaden, a 1‑point difference in PASDAS was associated with a mean (95% CI) difference in Patient’s Global Joint and Skin assessment (PGJS)-VAS score of 12.0 mm (11.6, 12.4) (OPAL Beyond: 12.6 mm [12.1, 13.1]). Mean (95% CI) PGJS scores corresponding to PASDAS low and high disease activity cut-offs, respectively, were 28.2 mm (27.1, 29.3) and 54.7 mm (53.6, 55.8) in OPAL Broaden (OPAL Beyond: 27.8 mm [26.3, 29.2] and 55.4 mm [54.1, 56.7], respectively).

Conclusion: The approximately linear association observed here provides insight into the relationship between PASDAS and examined PROs, some of which were components of PASDAS, while others were independent outcomes. Results were similar in both studies, suggesting that findings are consistent across different populations.

  1. Helliwell PS et al. Ann Rheum Dis 2013;72:986–91.
  2. Gladman D et al. N Engl J Med 2017;377:1525–36.
  3. Mease P et al. N Engl J Med 2017;377:1537–50.
  4. Helliwell PS et al. J Rheumatol 2014;41:1212–17.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Jennifer Higginson of CMC Connect and funded by Pfizer Inc.


Disclosure: L. Coates, Abbvie, 2, 5, 8, AbbVie, 2, 5, 8, AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Prothena, Sun Pharma, UCB, 5, Abbvie, Amgen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, 5, Abbvie, Amgen, Lilly, Novartis, Pfizer, UCB, 8, AbbVie, Celgene Corporation, Eli Lilly, Janssen, Novartis, UCB, 8, AbbVie, Celgene Corporation, Eli Lilly, Novartis, Pfizer, 2, AbbVie, Celgene Corporation, Novartis, Pfizer, 2, Abbvie, Celgene, Novartis, Pfizer, Lilly, 2, Amgen, 5, 8, Biogen, 8, Bristol-Myers Squibb, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, Gilead, 5, Janssen, 2, 5, 8, Janssen Research & Development, LLC, Lilly, 2, 5, 8, MSD, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 8, Prothena, 5, Sun Pharma, 5, UCB, 5, 8, UCB Pharma, 5; A. Bushmakin, Pfizer Inc, 1, 3; O. FitzGerald, AbbVie, 2, 8, Abbvie, 2, 8, BMS, 2, 5, Bristol Myers Squibb Co., 2, 5, Celgene, 5, Celgene Corp., 5, Janssen, 5, 8, Janssen Inc, 5, 8, Lilly, 2, 5, Novartis, 2, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 8; D. Gladman, AbbVie, 2, 5, AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 2, 5, Amgen, 2, 5, BMS, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 5, Gilead, 5, GlaxoSmithKline, 5, 8, Janssen, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, UCB, 2, 5; L. Fallon, Pfizer Inc, 1, 3; J. Cappelleri, Pfizer Inc, 1, 3, Pfizer Inc., 1, 3; M. Hsu, Pfizer Inc, 1, 3; P. Helliwell, AbbVie, 2, 8, Amgen, 8, Celgen, 8, Celgene, 8, Galapagos, 8, Janssen, 2, Janssen Research & Development, LLC, 2, Novartis, 2, Pfizer, 8, Pfizer Inc, 8, UCB, 8.

To cite this abstract in AMA style:

Coates L, Bushmakin A, FitzGerald O, Gladman D, Fallon L, Cappelleri J, Hsu M, Helliwell P. Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/relationships-between-psoriatic-arthritis-disease-activity-score-and-patient-reported-outcomes-in-patients-with-psoriatic-arthritis-post-hoc-analysis-of-two-phase-3-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationships-between-psoriatic-arthritis-disease-activity-score-and-patient-reported-outcomes-in-patients-with-psoriatic-arthritis-post-hoc-analysis-of-two-phase-3-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology